Multiomics and artificial intelligence enabled peripheral blood-based prediction of amnestic mild cognitive impairment - 03/02/23

Abstract |
Background |
Since dementia is preventable with early interventions, biomarkers that assist in diagnosing early stages of dementia, such as mild cognitive impairment (MCI), are urgently needed.
Methods |
Multiomics analysis of amnestic MCI (aMCI) peripheral blood (n = 25) was performed covering the transcriptome, microRNA, proteome, and metabolome. Validation analysis for microRNAs was conducted in an independent cohort (n = 12). Artificial intelligence was used to identify the most important features for predicting aMCI.
Findings |
We found that hsa-miR-4455 is the best biomarker in all omics analyses. The diagnostic index taking a ratio of hsa-miR-4455 to hsa-let-7b-3p predicted aMCI patients against healthy subjects with 97% overall accuracy. An integrated review of multiomics data suggested that a subset of T cells and the GCN (general control nonderepressible) pathway are associated with aMCI.
Interpretation |
The multiomics approach has enabled aMCI biomarkers with high specificity and illuminated the accompanying changes in peripheral blood. Future large-scale studies are necessary to validate candidate biomarkers for clinical use.
El texto completo de este artículo está disponible en PDF.Keywords : Mild cognitive impairment, Alzheimer's disease with dementia, Transcriptome, Proteome, Metabolome, Cohort, Biomarker, miRNA, Regulatory T cells
Abbreviations : MCI, AD, LOAD, NIA-AA, IHPP, MMSE, LMII, OLD, CDR, WMS-R, APOE, JPSC-AD, MRM, ROC, PCA, OPLS-DA, ISR, TCR, AUC, BBB, IPA
Esquema
Vol 71 - N° 1
Artículo 103367- janvier 2023 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
